The rationale of this study was to identify risk factors that predict early thrombotic events and angiographic restenosis after stenting in small coronary arteries. BACKGROUND Rates of cardiac complications and restenosis after percutaneous coronary intervention are higher in patients with small versus large coronary arteries. Because of discordant results, randomized studies comparing stent placement with balloon angioplasty could not establish the best interventional approach to use in this high-risk subset of patients. This study of predictive factors, with special focus on stent design, may provide particular help in this regard.
Percutaneous interventions in small coronary vessels (Ͻ3.0 mm) constitute a considerable proportion (30% to 50%) of the one million coronary catheter-based procedures performed worldwide each year. Percutaneous transluminal coronary angioplasty (PTCA) and stent placement are the two most frequently used interventions in patients with coronary artery disease (1) . Large coronary vessels represent an established indication for stenting, which is superior to PTCA, as shown in several randomized clinical trials (2, 3) . The role of systematic stent placement in small coronary arteries remains less well defined, with two randomized studies showing a significant reduction in angiographic restenosis rates (4, 5) , which could not be confirmed by two other comparable randomized studies (6, 7) . The factors responsible for this discrepancy are not known.
Several studies have assessed the predictive factors for major adverse cardiac events within the first 30 days, as well as for angiographic restenosis at six months after stent placement (8 -11) , but these findings may not be applicable to small coronary arteries owing to stent placement in large coronary arteries in the majority of patients. Furthermore, in most of the studies, the Palmaz-Schatz stent was the only type of stent used, and the impact of different stent designs on early and late outcomes in small coronary arteries is not known. A number of randomized trials have been undertaken to compare various stent models (12) (13) (14) (15) . Randomized trials often excluded patients with small coronary arteries and complex lesion morphologies. Therefore, their results may not be extrapolated to small coronary arteries. Studies focusing on this category of patients may help to explain the differences in the randomized stenting versus PTCA trials, resulting in a further refinement of the interventional approach.
In the present study, we analyzed the specific value of clinical, lesion-related, and procedural variables in predicting the risk of early thrombotic events and angiographic restenosis after stenting in a consecutive series of patients treated with various coronary stent designs in small coronary arteries.
METHODS
Patients. During a period of five years, coronary stent placement was performed in a consecutive series of 5,881 patients with symptomatic coronary artery disease. The population of the current study consisted of 3,156 patients with a reference vessel size Ͻ3.0 mm. Patients with unstable angina or acute myocardial infarction (MI) were included in this analysis. All patients were asked to undergo repeat angiography at six months, or earlier in the case of symptoms or objective signs of myocardial ischemia, as well as a clinical follow-up at 6 and 12 months. The protocol of routine clinical and angiographic follow-up studies has been approved by our institutional Ethics Committee. Stent placement and post-stenting treatment. During the intervention, patients received heparin and aspirin intravenously. In addition, 37.7% of patients considered at higher risk of stent thrombosis (acute MI, persistent thrombus at the stent site, large residual dissections) also received a glycoprotein IIb/IIIa inhibitor (e.g., a bolus and 12-h infusion regimen of abciximab). Post-procedural therapy consisted in 250 mg ticlopidine plus 100 mg aspirin twice daily for four weeks; aspirin was taken indefinitely.
Stents of various designs were inserted using either hand-crimped stents on conventional angioplasty balloons or the provided stent-delivery systems. The characteristics described subsequently for each stent type inserted in Ͼ100 patients in this series are those reported by the manufacturer. Most stent types had the slotted-tube design, including the classic Palmaz-Schatz stent (Johnson & Johnson Interventional Systems, Warren, New Jersey), the JO-Stent (JOMED International AB, Helsingborg, Sweden), and the Inflow stainless-steel stent (ID-Steel; Inflow Dynamics, Munich, Germany). The Inflow gold-plated stent (IDGold, Inflow Dynamics) is a stent with the same design as the ID-Steel stent, but it is plated with 0.005 mm of gold. The Pura-A stent (Devon Medical, Hamburg, Germany) has a slotted-tube design with longitudinal Y connections. The Multi-Link stent (Guidant, Advanced Cardiovascular Systems, Santa Clara, California) is made of a 0.050-mm stainless-steel wire that forms multiple rings connected with multiple links. The Multi-Link Duet stent (Guidant) also has an interconnected ring design, but the strut thickness is 0.140 mm. The NIR stent (Scimed, Boston Scientific Europe, Verviers, Belgium) has a continuous, uniform, multicellular design. Other stent types included the ACTOne and Paragon stents (Progressive Angioplasty Systems, Menlo Park, California), AVE GFX and Wiktor stents (Medtronic, Minneapolis, Minnesota), Crossflex and Crown stents (Johnson & Johnson Interventional Systems, Warren, New Jersey), Freedom stents (Global Therapeutics Inc., Broomfield, Colorado), ID Flex stents (Inflow Dynamics, Munich, Germany), Jomed graft stents (JOMED International AB, Helsingborg, Sweden), MAC and Omega stents (AMG, Raesfeld-Erle, Germany); all these stent types together were inserted in a total number of 118 patients. Angiographic evaluation. Lesions were classified according to the modified American College of Cardiology/ American Heart Association grading system (types A, B1, B2, and C). An automated edge-detection system (CMS version 4.0, Medis Medical Imaging Systems, Nuenen, The Netherlands) was used for off-line analysis of the digital angiograms. Matched views were selected for angiograms recorded before and immediately after the intervention and at follow-up. The variables obtained were lesion length, vessel size, minimal lumen diameter, diameter stenosis, and diameter of the maximally inflated balloon during stent placement. Late lumen loss was calculated as the difference in minimal lumen diameter measurements between after the procedure and at follow-up. Definitions. Procedural success was defined as stent placement at the desired site, with a satisfactory angiographic result (i.e., final residual stenosis Ͻ30%) and Thombolysis in Myocardial Infarction distal flow grade Ն2. Residual dissections at the end of the procedure were defined as Ͼ5-mm-long dissections (8) . An ejection fraction Ͻ50% was considered as reduced left ventricular (LV) function. The cumulative early thrombotic event rate was defined as death, nonfatal MI or documented stent occlusion, as demonstrated by angiography, occurring within the first 30 days after stent placement. The diagnosis of MI was based on typical chest pain combined with either new pathologic Q waves or a rise in creatine kinase Ͼ2 times the upper limit of normal (Ͼ160 U/l), with a concomitant increase in the MB isoenzyme. Target lesion revascularization (TLR) was performed in the presence of angiographic restenosis and typical chest pain or objective signs of myocardial ischemia. Patients with successful stent placement and without a major adverse cardiac event, including death, nonfatal MI, documented stent occlusion, or TLR within the first 30 days after stenting, were considered eligible for angiographic follow-up. Restenosis was defined as diameter stenosis Ն50% at follow-up angiography. Statistical analysis. Results are expressed as the mean value Ϯ SD or as proportions (%). Analysis of early clinical outcomes was performed on the entire patient population (n ϭ 3,156), whereas analysis of late angiographic outcomes was done on patients eligible for repeat angiography. All variables were entered into a multivariate logistic regression model to test for their independent effects. Analysis of early thrombotic events was made per patient, whereas analysis of restenosis was lesion-based. To eliminate a potential clustering effect in patients with a multilesion intervention (16), bootstrapping with 1,000 replications was applied for the calculation of regression coefficients, odds ratios, and 95% confidence intervals for each co-variate in the model, as well as for model calibration and validation (17) . To control the significance level when comparing different stent types (control for multiple comparisons), a closed-testing procedure was applied (18) . In a step-down manner, it started Hausleiter et al. September 4, 2002:882-9 Adverse Events and Restenosis in Small Coronary Arteries with a test of the global null hypothesis at a full alpha level.
In case of rejection, it proceeded with all null hypotheses on a lower stage, thus eliminating one group. If a null hypothesis could not be rejected, all hypotheses containing it were also rejected. With this test procedure, the significance alpha level can be controlled (18) . Statistical significance was defined as p Ͻ 0.05.
RESULTS
The analyzed variables were grouped into three categories: clinical, lesion-related, and procedural. In Tables 1 and 2 , these variables are summarized for all patients. Early clinical outcomes. The cumulative thrombotic event rate was 4.2% (n ϭ 133). This included, in the order of severity, 85 deaths (2.7%), 29 patients with nonfatal MI (0.9%), and 19 patients with angiographically documented stent occlusion (0.6%). Multivariate analysis for early thrombotic events. Figure  1 depicts eight clinical, lesion-related, and procedurerelated variables that were identified as independent risk factors for the occurrence of thrombotic events. The strongest independent predictors were the clinical variables: the presence of an acute coronary syndrome and reduced LV function (Table 3) . Among the procedure-related variables, the presence of a residual dissection at the end of the intervention was a strong predictor of thrombotic events. Female patients, as well as patients with complex, de novo, or long stented lesions, also had an increased risk of a major early adverse event. The stent design had no significant influence on early thrombotic events (p ϭ 0.38). Late angiographic outcome. Of the 3,156 study patients, 206 patients were not eligible for follow-up angiography because of an early thrombotic event (n ϭ 133), unsuccessful stent placement (n ϭ 32) and TLR within 30 days after stent placement (n ϭ 41). Repeat angiography at six months was carried out in 2,385 (80.8%) of 2,950 eligible patients.
A total of 2,978 lesions of 2,385 patients (1.17 lesions/ patient) were included for the six-month outcome analysis. The criterion for angiographic restenosis was reached in 916 (38.4%) of 2,385 patients. The TLR rate at one year was 20.7% (652 of 3,156 patients).
Multivariate analysis for angiographic restenosis. Figure  2A presents nine clinical, lesion-related, and procedurerelated variables as independent risk factors for restenosis. The stent design had the strongest independent influence among the procedural variables (Table 4) . Additional predictive factors included, in the order of significance, vessel size, stented segment length, lesion complexity, stenosis severity before the intervention, gender, balloon-to-vessel ratio, diabetes mellitus, and lesion length. Table 5 presents detailed information on baseline lesion characteristics and average late lumen loss, as well as restenosis and TLR rates, for the various stent designs. There were no significant differences in vessel size between the stent designs ranging from 2.57 Ϯ 0.30 mm for the Pura-A stent to 2.63 Ϯ 0.31 mm for the Duet stent (p ϭ 0.18). Lesion and stented segment length were significantly different between the stent types, with the highest values in the Multi-Link stent group (p Ͻ 0.001 for both variables). 
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At follow-up, there were significant differences in angiographic and clinical variables for restenosis between the stent designs. Compared with the Palmaz-Schatz stent, the Multi-Link stent resulted in 9.4% less late loss, a 19.6% lower restenosis rate, and a 10.2% lower rate of TLR. In contrast, use of the gold-plated Inflow stent resulted in a 28.2% increase in late loss, a 51.5% increase in the restenosis rate, and a 48.9% increase in the TLR rate. Figure 2B summarizes the results of the multivariate model with respect to stent design in terms of the adjusted risk of restenosis. Using the classic Palmaz-Schatz stent as a reference, placement of the Multi-Link stent was associated with the lowest risk of restenosis. With the JO-Stent, the risk of restenosis was lower than that with the PalmazSchatz stent; however, this did not reach statistical significance. It is also evident that most of the stents in this series (Duet, Palmaz-Schatz, Pura-A, ID-Steel, NIR) are not significantly different from each other in terms of risk, as shown in Figure 2B . However, the use of the ID-Gold stent was associated with a significantly higher risk of restenosis (odds ratio 1.81, confidence interval 1.30 to 2.51). Impact of clinical, lesion-related, and procedural variables on outcome. This analysis is based on three categories of factors: 1) clinical variables; 2) lesion-related variables; and 3) procedural-related variables (Tables 1 and 2 ). To assess each category's contribution to the strength of the final logistic regression models for early and late outcomes, we analyzed partial models with variables from the respective categories by using the chi-square value (Fig. 3) as an indicator of the predictive strength of the model. There is a striking difference between the two analyses: although clinical variables, including the presence of an acute coronary syndrome and reduced LV function, are the primary determinants of early thrombotic events, the importance of these factors for angiographic restenosis is diminished. The risk of restenosis is primarily determined by procedurerelated factors, including the stent design and length of the stented segment. The importance of lesion-related factors, including vessel size and lesion complexity, is subordinated in this patient cohort, whereas the relevance of clinical variables, with regard to restenosis, is small.
DISCUSSION
This is the first study to analyze the predictive factors for short-and long-term outcomes in a large cohort of unselected patients who underwent stent placement in coronary arteries with diameters Ͻ3.0 mm. Focusing on early outcomes, the study identified two major baseline clinical Hausleiter et al. September 4, 2002:882-9 Adverse Events and Restenosis in Small Coronary Arteries factors that were strong predictors of the occurrence of early thrombotic events: the presence of an acute coronary syndrome and reduced LV function. With respect to angiographically determined long-term outcomes, the study revealed two major findings: 1) procedural and lesion-related variables, but not baseline clinical factors, are the primary determinants of the risk of restenosis; and 2) the stent design is the strongest predictor of restenosis.
Although stent placement was initially approved by the U.S. Food and Drug Administration for use only in large coronary arteries (i.e., Ͼ3.0 mm), patients with smaller arteries constitute a large group of those treated with percutaneous coronary interventions in daily practice. Consequently, the outcome of patients with elective stent placement in small coronary arteries has been compared with the outcome of those treated with balloon angioplasty in several recent randomized trials (4 -7). As only two of four studies have shown a significant long-term benefit of routine stent placement (4, 5) , the advantage of a strategy of routine stent placement in small coronary arteries remains to be better studied. In the present study, we provide a comprehensive analysis of the risk of early thrombotic events after stenting and angiographic restenosis in a large population that had stent placement in small coronary arteries, including many patients with acute coronary syndromes who had been excluded from most previous trials. Predictors of early thrombotic events. In this analysis, a large number of factors were included: baseline clinical and lesion-related characteristics available before the intervention, as well as procedural factors describing the intervention and the final results. Eight factors were identified as significant and independent predictors of the occurrence of early thrombotic events. The most significant factors were two variables available before the intervention: the presence of an acute coronary syndrome and reduced LV function. In addition, the presence of a postprocedural dissection contributed significantly to the risk of thrombotic events. Our analysis of risk is in keeping with the results from previous analyses of larger vessels (8, 9) . These studies identified the influence of the aforementioned clinical variables, along with procedural factors, including lesion complexity and length of the stented segment, as risk factors for the occurrence of early stent thrombosis. The importance of *Derived from the logistic regression model for restenosis. †For these continuous variables, the median value was used as a cut-off point to define the two subgroups with the characteristic present or absent, and the values defining the 25th and 75th percentiles were used to calculate the respective odds ratios. ‡The odds ratios for the different stent types were calculated using the Palmaz-Schatz stent as a reference. CI ϭ confidence interval.
clinical risk factors identifiable before the interventional procedure indicates a need for individual risk stratification and a refined interventional approach (e.g., with an intensified antithrombotic regimen with potent glycoprotein IIb/IIIa inhibitors in a high-risk subset of patients).
Although it has been demonstrated that a coiled stent design may have a significant impact on the incidence of subacute stent thrombosis within the first month after stenting (13), our analysis did not identify the use of various noncoiled stent designs as an independent predictor of thrombotic events in this patient cohort with small coronary arteries. Predictors of restenosis. The predictive model for binary restenosis identified nine independent factors: female gender, diabetes mellitus, lesion complexity, long lesions, small vessel size, stenosis severity before the intervention, high balloon/vessel ratio, long stented segment, and stent design ( Fig. 2A) . Small vessel size, which was the second strongest risk factor in the current analysis, is a well-known potent predictor of restenosis after PTCA, as well as after stent placement (19 -22) . Elezi et al. (20) demonstrated that the risk of restenosis after stent placement may vary from 29.6% to 53.5% in patients with small coronary arteries (i.e., diameter Ͻ2.8 mm), depending on the presence of additional risk factors, such as complex lesion morphology and diabetes mellitus.
Most of the other identified predictors of restenosis are in keeping with earlier reports. However, the results of the earlier studies were confined to the sole use of the PalmazSchatz stent, and the influence of stent design has not been incorporated into the previous statistical models. In this series of patients with small coronary arteries, we used eight different stent designs of various slotted-tube and interconnected ring designs. In the current analysis, stent design was identified as a strong independent predictor of angiographic restenosis. This influence of stent design was also apparent in the analysis of angiographic late lumen loss and the need of TLR. The results are in agreement with four recent randomized clinical trials demonstrating that stent design (12, 13) , stent coating (23) and stent strut thickness (24) may determine restenosis-free survival. In most of these studies, patients with small coronary arteries and complex lesion morphologies were included. In contrast, several other randomized trials that excluded patients with small coronary arteries or complex lesion morphologies have failed to detect differences between different stent designs (14, 15) . Therefore, the results of our analysis suggest that the exclusion of patients with small coronary arteries may have masked differences among the tested stent designs in some previous trials.
When comparing elective stent placement with conventional PTCA in patients with small coronary arteries, two of four randomized trials have shown a significantly reduced restenosis rate after placement of a dedicated small vessel stent-the BeStent Small (Medtronic, Minneapolis, Minnesota) (4,5). Dedicated stents for small arteries have fewer (6) . Although the current study supports the hypothesis that a potential cause for the divergent trial results could be the use of different stent designs, our study also demonstrates that the design of the nondedicated Multi-Link stent is associated with the lowest restenosis rate in small coronary arteries, compared with the other stent designs used in this study. Therefore, it is unlikely that the differences in stent design between the BeStent Small and Multi-Link stent are the sole cause for the divergent trial results. Recently, we demonstrated a strong relationship between the residual stenosis grade after PTCA and restenosis reduction after stenting in a meta-analysis of stent versus PTCA trials in small coronary arteries (25) . Consequently, the residual stenosis grade achieved with PTCA has also been considered as a plausible explanation for the divergent trial results. Finally, relevant differences in patient and lesion characteristics, including lesion complexity and stented segment length, may also provide an additional explanation for the discrepancy of the study results. Study limitations. Although all data were prospectively collected with the objective of assessing the short-and long-term outcomes after stenting, the analysis was performed retrospectively. Of note, our main outcome measure-angiographic restenosis-was based on quantitative angiographic evaluations by operators blinded to the actual stent type used. However, additional randomized trials are required to establish the definite role of the stent type in restenosis development after stenting of small coronary arteries.
An additional limitation of the study is the absence of the BeStent Small, which has been used in three randomized trials comparing stenting with PTCA in small coronary arteries (4, 5, 7) . Finally, we acknowledge the limitation related to the availability of follow-up angiographic studies in 80.8% of patients. Previous trials of restenosis have also shown the impossibility of achieving higher rates because of patient refusal in an inevitable proportion of cases. Conclusions. Early thrombotic complications occurred in a low percentage of patients in this large, unselected population of 3,156 patients with stent placement in small coronary arteries. The predictors of early complications are predominantly clinical factors, including the presence of an acute coronary syndrome and reduced LV function, indicating the need for pre-interventional risk stratification, with an intensified antithrombotic regimen for high-risk patients. The development of angiographic restenosis is primarily influenced by procedural variables, particularly stent design. Therefore, judicious selection of stent designs is required before stenting of small coronary arteries.
